 gp100 Melanoma Antigen
"gp100 Melanoma Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A melanosome-associated protein that plays a role in the maturation of the MELANOSOME.
| Descriptor ID |
D058951
|
| MeSH Number(s) |
D12.776.543.306 D12.776.624.301.500 D23.050.285.439.500
|
| Concept/Terms |
gp100 Melanoma Antigen- gp100 Melanoma Antigen
- Antigen, gp100 Melanoma
- Melanoma Antigen, gp100
- gp100 Melanoma-Associated Antigen
- Antigen, gp100 Melanoma-Associated
- Melanoma-Associated Antigen, gp100
- gp100 Melanoma Associated Antigen
- ME20 Antigen
- Melanocyte Lineage-Specific Antigen gp100
- Melanocyte Lineage Specific Antigen gp100
- Melanocyte Protein Pmel 17
- Silver Locus Protein Homolog
- Melanoma-Associated Antigen gp100
- Melanoma Associated Antigen gp100
- Melanoma-Associated ME20 Antigen
- Antigen, Melanoma-Associated ME20
- ME20 Antigen, Melanoma-Associated
- Melanoma Associated ME20 Antigen
- MLSA gp100
- Pmel17 Melanoma Antigen
- Melanoma Antigen, Pmel17
- gp100 Melanocyte Differentiation Antigen
- Melanoma Antigen Glycoprotein 100
|
Below are MeSH descriptors whose meaning is more general than "gp100 Melanoma Antigen".
Below are MeSH descriptors whose meaning is more specific than "gp100 Melanoma Antigen".
This graph shows the total number of publications written about "gp100 Melanoma Antigen" by people in this website by year, and whether "gp100 Melanoma Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 2 | 2 | | 2000 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2006 | 0 | 4 | 4 | | 2016 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "gp100 Melanoma Antigen" by people in Profiles.
-
Klarquist J, Eby JM, Henning SW, Li M, Wainwright DA, Westerhof W, Luiten RM, Nishimura MI, Le Poole IC. Functional cloning of a gp100-reactive T-cell receptor from vitiligo patient skin. Pigment Cell Melanoma Res. 2016 May; 29(3):379-84.
-
Singh ZN, Tretiakova MS, Shea CR, Petronic-Rosic VM. Decreased CD117 expression in hypopigmented mycosis fungoides correlates with hypomelanosis: lessons learned from vitiligo. Mod Pathol. 2006 Sep; 19(9):1255-60.
-
Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother. 2006 Oct; 55(10):1185-97.
-
Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother. 2006 Jan-Feb; 29(1):95-101.
-
Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JF, Liau LM. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol. 2006 Jan 01; 176(1):157-64.
-
Sanchez-Perez L, Kottke T, Diaz RM, Ahmed A, Thompson J, Chong H, Melcher A, Holmen S, Daniels G, Vile RG. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res. 2005 Mar 01; 65(5):2009-17.
-
Hoang MP, Prieto VG, Burchette JL, Shea CR. Recurrent melanocytic nevus: a histologic and immunohistochemical evaluation. J Cutan Pathol. 2001 Sep; 28(8):400-6.
-
Ruhoy SM, Prieto VG, Eliason SL, Grichnik JM, Burchette JL, Shea CR. Malignant melanoma with paradoxical maturation. Am J Surg Pathol. 2000 Dec; 24(12):1600-14.
-
Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999 Jun; 5(6):677-85.
-
Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol. 1999 Feb 15; 162(4):2227-34.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|